News
The US Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above. Moderna expects to have the vaccine available for the 2025-2026 ...
Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...
Previously, Jivi was approved in September 2018 for adults and adolescents aged 12 years and older with this hemophilia subtype. 2 According to data collected from federally funded hemophilia ...
May 18 (UPI) --The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.The agency approved the vaccine only for people 65 and older ...
WASHINGTON (AP) — The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual restrictions. Novavax makes the nation’s only traditional ...
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include adults aged 18 to 59 who are at high risk of severe illness if they ...
Gilead Sciences, Inc.GILD obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the prevention of HIV.. The regulatory body approved lenacapavir, under the ...
Washington — The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual restrictions.. Novavax makes the nation’s only traditional ...
The US Food and Drug Administration is changing the way it approves Covid-19 vaccines for Americans, a move that may limit future shots to older Americans and people at higher risk of serious ...
The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...
Moderna, Pfizer/BioNTech and Novavax should target strains related to the JN.1 variant with their vaccines for next fall and winter because that strain is closer to the new variants of the virus ...
The FDA has approved AbbVie’s telisotuzumab vedotin (Emrelis) for locally advanced or metastatic, non-squamous non-small-cell lung cancer (NSCLC) with high c-MET protein overexpression after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results